– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – – Oral Plogosertib Preclinical Data Support Precision Medicine Strategy in ARID1A- and SMARCA-Mutated Cancers – – Management to Host Conference Call at 4:30 pm ET Today – BERKELEY HEIGHTS, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developi ...

watch nowQatar Airways is developing a First Class concept and pursuing aircraft orders from aviation giants Boeing and Airbus, as part of a broader strategic overhaul under new group CEO Badr Mohammed Al Meer."This is a new era," Al Meer told CNBC on Thursday, unveiling changes at the airline that follow a multi-month "war room" review. Formerly the chief operating officer of Qatar's Hamad International Airport, Al Meer took over from long-time predecessor Akbar Al Baker as Qatar Airways CEO in November an ...

Today’s article introduces three virtual reality stocks to buy. Once relegated to science fiction, VR is rapidly transforming from a futuristic concept to a tangible reality. Advancements in hardware, such as Apple‘s (NASDAQ:AAPL) Vision Pro and Meta Platform‘s (NASDAQ:META) Meta Quest 3, have greatly improved user experience and accessibility. After decades of anticipation, VR is finally delivering on its promise of immersive entertainment and revolutionizing various sectors, including healthcare with VR-a ...

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics primarily focused on the restoration of regulatory T cell (Treg) immunomodulatory function, announces the presentation of data demonstrating the role of the peripheral immune system in the pathophysiology of Frontotemporal Dementia (FTD) from a biomarker study conducted at the Houston Methodist Hospital by Dr. Stanley Appel and Dr. Alireza Faridar and funded by the Houston ...

Photographer: Michael Nagle/Bloomberg© 2024 Bloomberg Finance LPFor this month, the cycle/relative strength concept is applied. First, the Dow Jones 30 stocks are ranked from the best performer to the worst by calculating the expected return in that month. The top best traditional performers in the month were then screened for relative strength by a unique measure that sorts by several relevant time periods. Those that pass both screens are buys for the month. The stocks that are both weak monthly performer ...

CytomX Therapeutics (CTMX) is expected to report fourth-quarter and full-year 2023 results soon. In the last reported quarter, the company beat earnings expectations by 123.53%.Factors to NoteCytomX does not have any marketed product. Investor focus on the fourth-quarter 2023 earnings call will be on updates regarding key cancer immunotherapeutic candidates, CX-904 and BMS-986288.CX-904 is an EGFR-CD3 T-cell engager, developed in partnership with Amgen (AMGN) , while BMS-986288 is a non-fucosylated CTLA-4 t ...

Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2023 and provided an update on recent developments.  Company Updates Aethlon Medical is continuing the research and clinical development of its Hemopurifier®, a therapeutic blood filtr ...

NEW YORK--(BUSINESS WIRE)--Ark Restaurants Corp. (NASDAQ:ARKR) today reported financial results for the first quarter ended December 30, 2023. Financial Results Total revenues for the 13 weeks ended December 30, 2023 were $47,487,000 versus $47,445,000 for the 13 weeks ended December 31, 2022. The Company's EBITDA, excluding gains on the forgiveness of Paycheck Protection Program Loans (the "PPP Loan Forgiveness") and adjusted for other items all as set out in the table below, for the 13 weeks ended Dece ...

AUBURN HILLS, Mich., Feb. 12, 2024 /PRNewswire/ -- Chrysler is releasing a final teaser previewing a new, electrified concept car that offers a combination of seamless technology and battery-electric performance working in harmony with pure, streamlined, sustainability-inspired design.The reveal of the forward-looking concept can be viewed online at chrysler.com on Feb. 13, 2024, starting at 5:01 a.m. ET. Chrysler is releasing a final teaser previewing a new, electrified concept car that offers a combina ...

Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for treatment of patients with metastatic SCNC with progression on chemotherapy and no evidence of microsatellite instability BXCL701 is an investigational, oral innate immune activator designed to inflame the tumor microenvironment and augment CPI activity Company to discuss registration path at upcoming meeting with FDA NEW HAVEN, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical c ...